FEV Group: FEV develops AI-supported driver monitoring system CogniSafe
9.1.2025 11:05:03 CET | news aktuell GmbH | Press release
Aachen – FEV, a leading global innovation driver for the mobility of tomorrow, presents CogniSafe, a state-of-the-art Driver Monitoring System (DMS) that significantly increases road safety. The system uses advanced technologies such as deep learning and computer vision to monitor driver conditions such as distraction, fatigue and inattention in real time and under even the most challenging conditions.

“CogniSafe is a holistic, innovative system that uses a variety of sensors and combines them with artificial intelligence (AI) to precisely analyze driver behavior and alertness”, said Dr. Thomas Hülshorst, Group Vice President Intelligent Mobility & Software at FEV. In (semi-) autonomous vehicles in particular, legal safety requirements are increasing, and the driver must be able to intervene in any situation. “With our latest development, we are actively reducing accidents caused by human error. At over 90 percent, these make up the majority of all accidents,” said Hülshorst.
CogniSafe uses a combination of functions which are unique on the market and coordinate with each other. It uses a network of cameras in the visible light and infrared spectrum to analyze driver behavior from different angles. On this basis, the system continuously tracks the driver's gaze, analyzes eye condition (percentage of eye closure, PERCLOS) and assesses head posture, providing further information on alertness, fatigue and drowsiness.
AI plays a pivotal role in the functions of FEV's latest development. Convolutional Neural Networks (CNN) are used to perform precise real-time analyses that dynamically adapt to different drivers and environmental conditions, such as different lighting conditions, and continuously improve.
“The solution is also very interesting for target groups such as fleet operators or insurance companies, who have a strong interest in safe driving practices”, said Hülshorst.
Further information is available at https://shorturl.at/hy3dq
Marius Strasdat
T +49 241 5689-6452
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Webasto Air Top Pro 25: a new, exceptionally quiet parking heater for campers22.10.2026 13:52:44 CEST | Press release
Why should the camping season end just because summer is over? The colder months offer unique experiences—from skiing and snowshoeing to simply enjoying the winter landscape. To ensure your motorhome or campervan remains a comfortable retreat even in low temperatures, the right heating solution is crucial.
Polarise Launches Sovereign AI Cloud at NVIDIA GTC Berlin, Delivering Enterprise AI From Data Center to Application22.10.2026 10:00:00 CEST | Press release
With Polarise Rise and Polarise Drive, the German AI provider extends its own European AI Factories into a full-stack sovereign cloud
Democracy News Alliance: Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:55:20 CEST | Press release
New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found.
agineo expands partnership with ServiceNow, launches AI Control Tower as a Service20.10.2026 13:06:01 CEST | Press release
New managed service provides transparency into the AI landscape and helps companies centrally manage AI, monitor risks and regulatory requirements, and highlight business benefits.
Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 10:17:49 CEST | Press release
Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom